Codexis Q2 Revenue Jumps 79% on Enzyme Sales, Loss Narrows; Cash Runway Extended to 2028
CDXS sits 57% above its 52-week low of $0.958.
Summary
Codexis reported Q2 2026 product revenue of $13.2 million, up 79% YoY, and a narrower net loss of $12.0 million. The company reaffirmed guidance and extended its cash runway to 2028, supported by a $23.1 million public offering closed in July.
Key Events · Earnings and Guidance · CDXS
-
Product Revenue Surges 79%
Product revenue reached $13.2 million in Q2 2026, up from $7.4 million a year ago, driven by $1.7 million higher sales of enzymes for commercial pharma manufacturing and $4.1 million higher sales for clinical-stage manufacturing and process development.
-
Net Loss Narrows on Cost Cuts
Net loss improved to $12.0 million ($0.13/share) from $13.3 million ($0.16/share) a year ago, as total operating expenses fell 7% to $26.1 million, with R&D and SG&A both declining.
-
Cash Runway Extended to 2028
Management reaffirmed full-year guidance and stated that existing cash, combined with product revenue and expense management, provides adequate funds for at least the next 12 months, with the runway now extending to 2028 following the July 2026 public offering.
-
Subsequent $23.1M Public Offering
On July 27, 2026, Codexis closed an underwritten public offering of 16.7 million shares at $1.50 per share, raising $23.1 million in net proceeds. Underwriters partially exercised the over-allotment option for an additional 1.3 million shares on July 29.
Analysis · CDXS · Industrial Applications And Services
Codexis delivered a strong operational quarter with product revenue nearly doubling year-over-year, driven by higher enzyme sales for both commercial and clinical-stage manufacturing. The net loss narrowed as operating expenses fell, and management reaffirmed full-year guidance while extending the cash runway to 2028. The subsequent $23.1 million public offering closed in July further bolsters liquidity. The combination of accelerating product revenue, cost discipline, and extended runway reduces near-term survival risk, though the offering adds dilution.
At the time of this filing, CDXS was trading at $1.51 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $159.2M. The 52-week trading range was $0.96 to $3.87. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.